Prolonged progression‐free survival achieved by octreotide LAR plus transarterial embolization in low‐to‐intermediate grade neuroendocrine tumor liver metastases with high hepatic tumor burden

Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2020) M. Pavel et al.   ANNALS OF ONCOLOGY

Outcomes After Transarterial Embolization of Neuroendocrine Tumor Liver Metastases Using Spherical Particles of Different Sizes

(2019) Rebecca Zener et al.   CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY

Semi-quantitative visual assessment of hepatic tumor burden can reliably predict survival in neuroendocrine liver metastases treated with transarterial chemoembolization

(2019) Yan Luo et al.   EUROPEAN RADIOLOGY

Clinical analysis of 547 patients with neuroendocrine tumors in a Chinese population: A single‐center study

(2019) Lijie Song et al.   Cancer Medicine

Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study

(2019) Alberto Carmona-Bayonas et al.   JOURNAL OF CLINICAL ONCOLOGY

Quantitative Pretreatment CT Parameters as Predictors of Tumor Response of NET Liver Metastasis to TAE

(2019) Yiming Liu et al.   NEUROENDOCRINOLOGY

Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real‐World Data from the Spanish Tumor Registry (R‐GETNE)

(2018) Barbara Nuñez‐Valdovinos et al.   ONCOLOGIST

DAXX Mutation Status of Embolization-Treated Neuroendocrine Tumors Predicts Shorter Time to Hepatic Progression

(2018) Etay Ziv et al.   JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY

Pancreatic neuroendocrine neoplasms: Correlation between MR features and pathological tumor grades

(2017) Feng Jin et al.   Journal of Huazhong University of Science and Technology-Medical Sciences

Bone Metastases in Patients with Neuroendocrine Neoplasm: Frequency and Clinical, Therapeutic, and Prognostic Relevance

(2017) Michael Scharf et al.   NEUROENDOCRINOLOGY

Transarterial (Chemo)Embolization for Liver Metastases in Patients with Neuroendocrine Tumors

(2017) Hiroyuki Okuyama et al.   ONCOLOGY

Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States

(2017) Arvind Dasari et al.   JAMA Oncology

Chemoembolization of Neuroendocrine Liver Metastases Using Streptozocin and Tris-acryl Microspheres: Embozar (EMBOsphere + ZAnosaR) Study

(2016) Jean-Pierre Pelage et al.   CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY

Embolotherapy for Neuroendocrine Tumor Liver Metastases: Prognostic Factors for Hepatic Progression-Free Survival and Overall Survival

(2016) James X. Chen et al.   CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY

Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study

(2016) Martyn E Caplin et al.   ENDOCRINE-RELATED CANCER

Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival

(2016) Anja Rinke et al.   NEUROENDOCRINOLOGY

Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors

(2014) Martyn E. Caplin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Extrahepatic Disease Should Not Preclude Transarterial Chemoembolization for Metastatic Neuroendocrine Carcinoma

(2013) David Arrese et al.   ANNALS OF SURGICAL ONCOLOGY

Survival Outcomes and Prognostic Factors of Transcatheter Arterial Chemoembolization for Hepatic Neuroendocrine Metastases

(2013) Saebeom Hur et al.   JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY

Factors Affecting Periprocedural Morbidity and Mortality and Long-term Patient Survival after Arterial Embolization of Hepatic Neuroendocrine Metastases

(2013) Constantinos T. Sofocleous et al.   JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY

A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors

(2012) J. R. Strosberg et al.   ANNALS OF ONCOLOGY

Phase II Study of Chemoembolization With Drug-Eluting Beads in Patients With Hepatic Neuroendocrine Metastases: High Incidence of Biliary Injury

(2012) Nikhil Bhagat et al.   CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY

Hepatic Arterial Embolization versus Chemoembolization in the Treatment of Liver Metastases from Well-Differentiated Midgut Endocrine Tumors: A Prospective Randomized Study

(2012) Frédérique Maire et al.   NEUROENDOCRINOLOGY

Relationship between clinical characteristics and survival of gastroenteropancreatic neuroendocrine neoplasms: A single-institution analysis (1995–2012) in South China

(2012) Yu-hong Wang et al.   BMC Endocrine Disorders

Liver Metastases of Neuroendocrine Tumors: Treatment With Hepatic Transarterial Chemotherapy Using Two Therapeutic Protocols

(2009) Thomas J. Vogl et al.   AMERICAN JOURNAL OF ROENTGENOLOGY

Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic disease

(2009) A. Frilling et al.   BRITISH JOURNAL OF SURGERY

Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group

(2009) Anja Rinke et al.   JOURNAL OF CLINICAL ONCOLOGY

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER